Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

CTAD 2022 | New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway

Aaron Koenig, MD, Sage Therapeutics Inc., Cambridge, MA, explains the rationale behind targeting the NMDA pathway for the treatment of mild cognitive impairment (MCI) and mild dementia due to Alzheimer’s disease (AD) using a new investigational compound, SAGE-718. Previous research has demonstrated a relative NMDA deficit early in the course of neurodegenerative diseases such as AD. SAGE-718 is a positive allosteric modulator of the NMDA receptor and treatment with SAGE-718 could restore NMDA tone and therefore improve symptoms of cognitive decline. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


•Aaron Koenig is an employee of Sage Therapeutics, Inc., and may hold stock and/or stock options.
•The LUMINARY and LIGHTWAVE studies are sponsored by Sage Therapeutics, Inc.
•SAGE‐718 is an investigational drug and is not approved by the US Food and Drug Administration or any other regulatory agency as safe and effective for any use.